Codethink, Ltd. Joins Eclipse Foundation and Eclipse SDV Working Group as Strategic Member to Advance Trustable Software Collaboration
7.1.2025 16:00:00 CET | Business Wire | Press Release
Codethink, Ltd., a global leader in software engineering services and solutions, today announced its membership in the Eclipse Foundation and the Eclipse SDV Working Group as a Strategic Member. This milestone reflects Codethink’s commitment to driving innovation and industry standards in the emerging field of trustable software.
As part of its membership, Codethink will collaborate with the Eclipse Foundation and its global network of members to advance the concept of trustable software—software that is auditable, transparent, and suitable for use in critical systems and supply chains. In addition, Codethink will contribute key technologies and intellectual property from its Trustable Software portfolio to accelerate industry progress and stimulate innovation.
“Codethink is honoured to join the Eclipse Foundation and the Eclipse SDV Working Group as a Strategic Member,” said Paul Sherwood, Chairman of Codethink, Ltd. “We believe trustable software is essential to the secure and reliable operation of modern digital systems. By contributing our expertise and collaborating with industry leaders, we are paving the way for more transparent and reliable software solutions across the globe.”
The Eclipse Foundation welcomed Codethink’s decision to join its strategic membership ranks. “Codethink’s leadership in trustable software development brings critical capabilities to our community,” said Mike Milinkovich, Executive Director of the Eclipse Foundation. “Their contributions will further strengthen our collective efforts to ensure transparency, auditability, and trust in software systems.”
Codethink’s collaboration will benefit from the expertise of key partner exida, the world’s leading product certification and knowledge company specializing in automation system safety, alarm management, cybersecurity, and availability.
"Codethink's trustable model is a much-needed upgrade to the underlying principles of functional safety and cybersecurity designed for modern large-scale very complex software engineering and a best practice suitable for the architectures and deployments in use now and the future," said Jonathan Moore, director, advanced systems, exida LLC. “We look forward to collaborating on frameworks and standards that will set new benchmarks for software certification and assurance.”
Codethink’s membership with the Eclipse Foundation marks a significant step in fostering global industry collaboration to address the growing need for transparent, auditable, safe and secure software solutions.
For more information, visit www.codethink.co.uk or www.eclipse.org.
About Codethink
Codethink is a world-class provider of critical, high-performance software projects and solutions for international-scale companies in a range of industries including Automotive, Finance, Medical, and IoT. Headquartered in Manchester, UK, Codethink has pioneered software industry thinking around concepts of trustable software, working to improve the quality of software engineering.
About the Eclipse Foundation
The Eclipse Foundation provides our global community of individuals and organisations with a business-friendly environment for open source software collaboration and innovation. We host the Eclipse IDE, Adoptium, Software Defined Vehicle, Jakarta EE, and over 420+ open source projects, including runtimes, tools, specifications, and frameworks for cloud and edge applications, IoT, AI, automotive, systems engineering, open processor designs, and many others. Headquartered in Brussels, Belgium, the Eclipse Foundation is an international non-profit association supported by over 385 members. To learn more, follow us on X, LinkedIn or visit eclipse.org.
About exida
exida is a certification and research firm specializing in safety critical/high availability automation systems, control system cybersecurity, and alarm management. exida has performed more process control certifications and assessments than any other company worldwide. exida’s main offices are located in Sellersville, Pa., USA, and Munich, Germany and has worldwide operations with service centers in Brazil, Canada, Mexico, Netherlands, and New Zealand, Singapore, Japan, South Africa, and the United Kingdom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107724841/en/
Contacts
Media:
Amanda Keane
Vice President, Racepoint Global
akeane@racepointglobal.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press Release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press Release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press Release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press Release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press Release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom